# Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease

Study · id `cardio:ct-nct07911124` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07911124](<https://clinicaltrials.gov/study/NCT07911124>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07911124

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 230 participants.

## Technical summary

Registry record NCT07911124. Randomized; quadruple masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2030-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 230 participants (planned count; ClinicalTrials.gov record NCT07911124, source copy `cardio:ctgov-nct07911124-2026-11-10`, retrieved 2026-11-18)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07911124, source copy `cardio:ctgov-nct07911124-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2030-12 (anticipated) (ClinicalTrials.gov record NCT07911124, source copy `cardio:ctgov-nct07911124-2026-11-10`, retrieved 2026-11-18)
- Completion: 2031-07 (anticipated) (ClinicalTrials.gov record NCT07911124, source copy `cardio:ctgov-nct07911124-2026-11-10`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07911124, source copy `cardio:ctgov-nct07911124-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07911124-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease
- Acronym: TACTIC-CKD
- Condition: Chronic Kidney Disease (CKD)
- Intervention (Drug): Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist
- Intervention (Drug): Placebo
- Lead sponsor: University of Arkansas
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: University of Arkansas (`cardio:org-university-of-arkansas`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 681cee249588c530b6581120c85e0718b21d6bb4a6fc03e8ed56df91d0481d22
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
